Hematology Oncology Department, Hotel Dieu de France Hospital, Beirut, Lebanon.
Hematology Oncology Department, Hotel Dieu de France Hospital, Beirut, Lebanon.
Clin Lymphoma Myeloma Leuk. 2023 Dec;23(12):866-873. doi: 10.1016/j.clml.2023.08.014. Epub 2023 Aug 21.
Primary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under investigation have improved patient outcomes. This review summarizes the different treatment modalities in (PMBCL) in the frontline and the relapsed/refractory settings.
原发性纵隔 B 细胞淋巴瘤 (PMBCL) 根据世界卫生组织 (WHO) 淋巴系统恶性肿瘤分类被视为一种独特的疾病。在蒽环类药物为基础的化疗中加入利妥昔单抗后，患者的预后更好。在批准剂量调整的 R-EPOCH 方案后，巩固性放疗的作用存在争议，并且对接受放疗的患者的选择是基于治疗结束时的 PET CT。在复发/难治性疾病中，新批准的药物和其他正在研究的药物改善了患者的预后。本文综述了原发性纵隔 B 细胞淋巴瘤在一线和复发/难治性疾病中的不同治疗方法。
